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Abstract: A series of 7-azaindolyl hydrazones were prepared by reacting of hydrazides of 7-azaindole-3-acetic acids with aromatic aldehydes 
and N-substituted indolyl-3-carboxyaldehydes. Structure of all the synthesized compounds were satisfactorily correlated by IR, 1H NMR, 13C 
NMR and mass spectroscopic evidences. The synthesized compounds were evaluated for their possible anticancer potential against MCF-7 
induced breast carcinoma. It is worth mentioning that most of the compounds were considerably active against MCF-7 cell line with GI50 values 
ranging from 22.3–81.0 μM. The hydrazones of N-1-substituted indole-3-carboxyaldehydes 9f, 9g, 9h, 9c, and 9j were active against MCF-7 cell 
line with GI50 values less than 40 μM (GI50 = 22.3 and 24.9, 29.6, 30.2 and 37.8 μM respectively) with moderate TGI values (TGI = 56.6, 59.5, 
65.5, 70.7 and 94.6 μM respectively). The active compounds were also screened against the normal Vero monkey cell line, which showed 
moderate selectivity against inhibition of cancer cells. 
 





NDOLE is the most active pharmacophoric nucleus and 
major constituent of number of bio-molecules viz in-
dole-3-acetic acid (IAA), oncracin-1, indole 3-carbinol (I3C), 
tryptophan, serotonin and melatonin.[1] It is also found in 
various natural compounds such as alkaloids.[2] The substi-
tuted bis-indole derivatives like nortopsentin, coscinamide 
A-C, indibulin, rhopaladin, labradorin, tenidap and ap-
lysinopsins exhibited various pharmacological properties 
such as anti-inflammatory, analgesic and antitumor.[3] One 
of the preferred approaches during drug development is to 
synthesize analogues of the lead compound. In this regard 
indole can be replaced with azaindole where the main core 
would be replaced with bioisosteric conceptual atom and 
to evaluate the effect on activity. This approach may en-
hance the biological activity with reducing side effects.  
Among the various bioisosters of azaindole,[4] 7-azaindole 
has received a great deal of attention due to wide variety 
of biological activities (Figure 1).[5,6] Similarly, the functional 
framework of hydrazide / hydrazone (-CO-NH-N=CH-) has 
applications in building heterocyles[7] with potential anti-in-
flammatory, antimalarial, anticonvulsant, anti-tuberculo-
sis, antitumor, and antimicrobial activities.[8] Apart from 




Figure 1. Bioactive compounds having hydrazide, hydrazone 
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have been studied and applied in supramolecular chemis-
try, metal and covalent organic framework, dynamic com-
binatorial chemistry, dyes and pigments chemistry.[9] 
 In continuation of our studies in synthesizing various 
biologically active compounds[10] and all the above men-
tioned facts guided us to design and synthesize novel  




Materials and Methods 
All the chemicals used were of synthetic grade and pro-
cured from Sd-fine, Spectrochem and Aldrich chemicals. 
Completion of the reactions was monitored by thin layer 
chromatography (TLC) using E-Merck 0.25 mm silica gel 
plates using methanol: chloroform (1 : 9) as eluting me-
dium. Visualization was accomplished with UV light and or 
iodine vapors. All the solvents were dried using appropriate 
drying agents before use. Melting points were determined 
by open end capillary method and are uncorrected. All the 
1H NMR spectra were recorded in DMSO-d6 / CDCl3 and 
chemical shifts in ppm were reported on instrument Bruker 
AV-400 MHz, for 1H NMR and 75 MHz for 13C NMR relative 
to TMS as an internal standard. The IR spectra were 
recorded on Shimadzu FT-IR spectrophotometer by using  
1 % potassium bromide discs. The electron ionization mass 
spectra were recorded on Agilent 1100 series. 
Synthesis 
PROCEDURE FOR PREPARATION OF (2-METHYL-1H-
PYRROLO[2,3-B]PYRIDIN-3-YL)ACETIC ACID METHYL 
ESTER (4) 
The 2-methyl-7-azaindole-3-acetic acid (3)[11] (10 mmol) 
were esterified in a classical manner with methanol and cat-
alytic amount of con H2SO4 under reflux for 7 h. After com-
pletion, the reaction mixture was cooled and solvent 
methanol was removed under reduced pressure. The residue 
was then poured onto crushed ice and extracted repeatedly 
with ethyl acetate. The ethyl acetate layer was washed with 
saturated sodium bicarbonate solution followed by water. 
The ethyl acetate layer was dried over sodium sulphate and 
distilled off under reduced pressure. The solid product ob-
tained was filtered, washed with cold ethyl acetate and dried.  
 Yield: 82 %; m.p. 182–184 °C; IR (KBr, cm–1): 3154 
(NH), 2952 (CH), 1730 (C=O), 1626, 1586, 1558; 1H NMR 
(400 MHz, CDCl3) δ / ppm: 2.55 (s, 3H, CH3), 3.70 (s, 3H, 
CH3), 3.73 (s, 2H), 7.07–7.10 (m, 1H, ArH), 7.88 (d, J = 4.0 Hz, 
1H, ArH), 8.25 (d, J = 4.0 Hz, 1H, ArH), 12.03 (s, 1H, NH), 13C 
NMR (75 MHz, CDCl3): 21.83, 30.11, 51.97, 102.41, 115.39, 
121.56, 126.35, 134.29, 140.64, 148.32, 172.29;  ESI-MS:  
m / z 205.0 (M+1). 
PROCEDURE FOR PREPARATION OF (2-METHYL-1H-
PYRROLO[2,3-B]PYRIDIN-3-YL)ACETIC ACID  
HYDRAZIDE (5) 
A solution of hydrazine hydrate (15 mL, 99 %) was added to 
a solution of methyl ester of 2-methyl-7-azaindole-3-acetic 
acid 4 (10 mmol) in methanol (25 mL). The reaction mixture 
was refluxed for 5 h. At the end of reaction monitored by 
TLC, the reaction mixture was evaporated under reduced 
pressure to ¼ volume and by cooling the white crystalline 
pure product was obtained. 
 Yield: 85 %; m.p. 192–194 °C; IR (KBr, cm–1): 3155, 
2952 (CH), 1626 (C=O), 1600 (C=C), 1196, 1167, 993, 796, 
769, 664, 652; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.35 
(s, 3H, CH3), 3.38 (s, 2H, CH2), 4.17 (s, 2H, NH2), 6.95 (dd, J = 
6.8 and 4.0 Hz, 1H, ArH), 7.85 (d, J = 8.0 Hz, 1H, ArH), 8.06 
(d, J = 5.2 Hz, 1H, ArH), 9.13 (s, 1H, NH), 11.29 (s, 1H, Indole-
NH); ESI-MS: m/z 205.1 (M+1). 
 
GENERAL PROCEDURE FOR PREPARATION OF 
HYDRAZONE DERIVATIVES (8a–l) 
A mixture of (2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-ace-
tic acid hydrazide 5  (1.0 mmol)  and substituted aromatic 
benzaldehyde 6a–l (1.0 mmol) in 10 mL of ethanol and few 
drops of glacial acetic acid was stirred for 3–4 h at room 
temperature. A solid was separated out within 15– 
20 minutes and the stirring was continued for 3–4 h to com-
plete the reaction. The reaction progress was monitored by 
TLC (chloroform / methanol). After completion of the reac-
tion, the product was collected with vacuum filtration and 
washed with cold ethanol to give off white crystals of the 




Yield: 91 %; m.p. 272–274 °C; IR (KBr, cm–1): 3155, 3064, 
2944, 2763, 1667, 1542, 1473, 1408, 1348, 1295, 1165, 
1143, 1100, 1313, 907, 822, 737; 1H NMR (400 MHz, DMSO-
d6) δ / ppm: 2.36 (s, 3H, CH3), 4.03 (s, 2H, CH2), 6.95 (dd, J = 
4.8 and 2.8 Hz, 1H, ArH), 7.51 (d, J = 8.8 Hz, 1H, ArH), 7.70–
7.71 (m, 1H, ArH), 7.80 (d, J = 7.6 Hz, 1H, ArH), 8.07-8.08 (m, 
2H, ArH), 8.34 (s, 1H, N=CH), 11.32 (s, 1H, NH), 11.54 (s, 1H, 
CONH); 13C NMR (75 MHz, DMSO-d6): 11.87, 28.27, 103.20, 
115.27, 121.14, 126.05, 128.39, 129.77, 131.08, 134.17, 
134.52, 135.22, 138.43, 141.63, 148.24, 167.81, 173.15; 




Yield 86 %; m.p. 239–241 oC; IR (KBr, cm–1): 3146, 3075 (N-
H), 2944, 2913, 1670, 1613,  1552, 1526, 1497, 1469, 1341, 
1188, 828; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.36 (s, 
3H, CH3), 4.03 (s, 2H, CH2), 6.95 (dd, J = 4.8 and 2.8 Hz, 1H, 
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7.93 (d, J = 8.4 Hz, 1H, ArH), 8.07-8.08 (m, 2H, ArH), 8.34 (s, 
1H, N=CH), 11.32 (s, 1H, NH), 11.54 (s, 1H, CONH); ESI-MS: 




Yield 93 %; m.p. 259–261 °C; IR (KBr, cm–1): 3197, 3066, 
2987, 2940, 1669, 1579, 1499, 1465, 1368, 1156, 954, 806, 
769, 664; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.39 (s, 3H, 
CH3), 3.58 (s, 2H, CH2), 3.70 (s, 3H OCH3), 3.82 (s, 6H, 2-
OCH3), 6.91–6.93 (m, 1H, ArH), 6.95 (s, 1H, ArH), 7.02 (s, 1H, 
ArH), 7.87–7.91 (m, 1H, ArH), 8.05–8.08 (m, 1H, ArH), 8.17 
(s, 1H, N=CH), 11.32 (s, 1H, NH), 11.46 (s, 1H, CONH); ESI-




Yield 90 %; m.p. 235–237 oC; IR (KBr, cm–1): 3206, 3063, 
2941, 2901, 1665, 1624, 1588, 1547, 1489, 1450, 1389, 
1199, 1185, 1007, 867,  716, 666; 1H NMR (400 MHz, DMSO-
d6) δ / ppm: 2.39 (s, 3H, CH3), 3.98 (s, 2H, CH2), 6.08 (s, 2H, 
OCH2), 6.95–6.98 (m, 2H, ArH), 7.11 (d, J = 8.0 Hz, 1H, ArH), 
7.21-7.33 (m, 1H, ArH), 7.82–7.90 (m, 1H, ArH), 8.04–8.07 
(m, 1H, ArH), 8.15 (s, 1H, N=CH), 11.19 (s, 1H, NH), 11.38 (s, 




Yield 86 %; m.p. 239–241 oC; IR (KBr, cm–1): 3146, 3075 (N-
H), 2944, 2913, 1670, 1613, 1552, 1526, 1497, 1469, 1341, 
1188, 828; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.36 (s, 
3H, CH3), 4.03 (s, 2H, CH2), 6.95 (dd, J = 4.8 and 2.8 Hz, 1H, 
ArH), 7.51 (d, J = 8.8 Hz, 1H, ArH), 7.70–7.72 (m, 1H, ArH), 
7.93 (d, J = 8.4 Hz, 1H, ArH), 8.07–8.08 (m, 2H, ArH), 8.34 (s, 
1H, N=CH), 11.32 (s, 1H, NH), 11.54 (s, 1H, CONH); ESI-MS: 




Yield 85 %; m.p.238–240 oC; IR (KBr, cm–1): 3154, 3079, 
2953, 1673, 1560, 1531, 1471, 1439, 1588, 1347, 1293, 
1144, 954, 736; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.40 
(s, 3H, CH3), 4.04 (s, 2H, CH2), 6.92–6.93 (m, 1H, ArH), 7.72–
7.74 (m, 1H, ArH), 7.83–7.85 (m, 1H, ArH), 8.06–8.16 (m, 
3H, ArH), 8.37 (s, 1H, N=CH), 8.50-8.54 (m, 1H, ArH), 11.37 




Yield 85 %;  m.p. 280–282 oC; IR (KBr, cm–1): 3199, 3060, 
2997, 2940, 1667, 1578, 1497, 1462, 1368, 1156, 952, 806, 
767, 664; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.33 (s, 3H, 
CH3), 3.76 (s, 3H, OCH3), 3.82 (s, 6H, OCH3), 3.92 (s, 2H, CH2), 
6.30 (s, 2H, ArH), 6.89–6.92 (m, 1H, ArH), 7.89–7.90 (m, 1H, 
ArH), 8.03–8.04 (m, 1H, ArH), 8.15 (s, 1H, N=CH), 10.91 (s, 




Yield 89 %; m.p. 290–292 oC; IR (KBr, cm–1): 3156, 3062, 
2952, 1672, 1588, 1558, 1468, 1443, 1343, 1270, 1068, 887, 
703, 682; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.39 (s, 3H, 
CH3), 4.01 (s, 2H, CH2), 6.92–6.95 (m, 1H, ArH), 7.37–7.42 
(m, 1H, ArH), 7.59–7.61 (m, 1H, ArH), 7.65–7.70 (m, 1H, 
ArH), 7.82–7.87 (m, 1H, ArH), 7.96 (s, 1H, ArH), 8.05–8.08 
(m, 1H, ArH), 8.20 (s, 1H, N=CH), 11.41 (s, 1H, NH), 11.63 (s, 




Yield 92 %; m.p. 270–272 oC; IR (KBr, cm–1): 3649, 3195, 
3047, 2938, 2902, 1671, 1572, 1441, 1417, 1286, 1183, 902, 
736; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.41 (s, 3H, 
CH3), 3.96 (s, 2H, CH2), 6.70–6.75 (m, 1H, ArH), 6.95–6.98 
(m, 1H, ArH), 7.31 (s, 1H, ArH), 7.76–7.82 (m, 1H, ArH), 
8.03–8.07 (m, 3H, ArH), 8.13 (s, 1H, N=CH), 9.43 (s, 1H, -





Yield 86 %; m.p. 210–212 oC; IR (KBr, cm–1): 3649, 3246, 
3156, 3059, 2994, 2943, 1667, 1577, 1549, 1470, 1440, 
1189, 1020, 871; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 
2.39 (s, 3H, CH3), 3.88 (s, 3H, OCH3), 3.99 (s, 2H, CH2), 6.91–
6.94 (m, 1H, ArH), 7.20–7.24 (m, 1H, ArH), 7.46 (d, J = 8.0 Hz, 
1H, ArH), 7.60 (d, J = 12.0 Hz, 1H, ArH), 7.83 (d, J = 7.6 Hz, 1H, 
ArH), 7.92 (s, 1H, N=CH), 8.04-8.07 (m, 1H, ArH), 11.26 (s, 1H, 




Yield 90 %; m.p. 230–232 oC; IR (KBr, cm–1): 3649, 3222, 
3201, 3047, 2836, 1664, 1543, 1514, 1455, 1430, 1388, 
1144, 1075, 955, 803; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 
2.39 (s, 3H, CH3), 3.81 (s, 3H, OCH3), 3.98 (s, 2H, CH2), 6.79–
6.83 (m, 1H, ArH), 6.91–6.94 (m, 1H, ArH), 6.96–6.99 (m, 1H, 
ArH), 7.31 (s, 1H, ArH), 7.82–7.88 (m, 1H, ArH), 8.04–8.07 (m, 
1H, ArH), 8.12 (s, 1H, N=CH), 9.49 (s, 1H, OH), 11.26 (s, 1H, 
NH), 11.45 (s, 1H, CONH); ESI-MS: m/z 339.2 (M+1). 
 
N'-(4-Cyanobenzylidene)-2-(2-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl) acetohydrazide (8l) 
Yield 88 %; m.p. 195–197 oC; IR (KBr, cm–1): 3650, 3242, 
3208, 3156, 3050, 2843, 2764, 2227, 1670, 1505, 1460, 




4 S. B. DONGARE et al.: Design, Synthesis, and Spectroscopic Study … 
 




(400 MHz, DMSO-d6) δ / ppm: 2.43 (s, 3H, CH3), 3.98 (s, 2H, 
CH2), 6.72–6.77 (m, 1H, ArH), 6.96–6.98 (m, 1H, ArH), 7.76 
(d, J = 8 Hz, 2H), 8.03–8.09 (m, 3H), 8.13 (s, 1H, N=CH), 11.26 
(s, 1H, NH), 11.49 (s, 1H, CONH); ESI-MS: m / z 318.2 (M+1). 
 
GENERAL PROCEDURE FOR PREPARATION OF 
HYDRAZONE DERIVATIVES (9a–j) 
A mixture of 2-(2-methyl-1H-pyrrolo[2,3-b]pyridine-3-
yl)acetohydrazide 5 (1.0 mmol) and N-1 substituted-indole-
3-carbaldehyde 7a–j (1.0 mmol) in 10 ml ethanol and few 
drops of glacial acetic acid was refluxed for 3–4 h to com-
plete the reaction. The reaction progress was monitored by 
TLC (chloroform/methanol). After completion of the reac-
tion, the mixture was cooled to room temperature and col-
lected the product with filtration and washed with cold 




Yield 81 %; m.p. 192–194 oC; IR (KBr, cm–1): 3154, 3067, 
2941, 2842, 1668, 1583, 1545, 1491, 1460, 1235, 1141, 762; 
1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.33 (s, 3H, CH3), 
4.07 (s, 2H, CH2), 5.46 (s, 2H), 6.87–6.90 (m, 1H ), 7.10–7.29 
(m, 4H), 7.37–7.40 (m, 1H), 7.47–7.52 (m, 1H), 7.81 (d, J = 
7.2 Hz, 1H), 7.95-7.98 (m, 1H), 7.98 (s, 1H), 8.05 (d, J =  
4.0 Hz, 1H), 8.17-8.20 (m, 1H), 8.22 (s, 1H), 11.06 (s, 1H, 
NH), 11.32(s, 1H, CONH); ESI-MS: m / z 456.29 (M+). 
 
N'-((1-(4-Fluorobenzyl)-1H-indol-3-yl)-methylene)-2-(2-
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl) acetohydrazide (9b) 
Yield 83 %; m.p. 210–212 oC; IR (KBr, cm–1): 3158, 3054, 
2939, 2843, 1640, 1574, 1562, 1445, 1418, 1292, 1156, 747; 
1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.37 (s, 3H, CH3), 
4.06 (s, 2H, CH2), 5.44 (s, 2H, N-CH2), 6.87–6.90 (m, 1H, 
ArH), 7.14–7.21 (m, 3H, ArH), 7.31–7.33 (m, 2H, ArH), 7.55 
(d, J = 8.0 Hz, 1H, ArH), 7.81 (d, J = 7.2 Hz, 1H, ArH), 7.95–
7.98 (m, 1H, ArH), 7.98 (s, 1H, ArH), 8.05 (d, J = 4.0 Hz, 1H, 
ArH), 8.17–8.19 (m, 1H, ArH), 8.22 (s, 1H,N=CH), 11.10 (s, 





Yield 84 %; m.p. 201–203 oC; IR (KBr, cm–1): 3155, 3064, 
2944, 1667, 1587, 1558, 1473, 1441, 1371, 1261, 1054, 868, 
809; 1H NMR (400 MHz, DMSO-d6): δ / ppm = 2.38 (s, 3H, 
CH3), 4.07 (s, 2H, CH2), 5.54 (s, 2H, N-CH2), 6.76–6.80 (m, 
1H, ArH), 6.88–6.91 (m, 1H, ArH), 7.13–7.24 (m, 2H, ArH), 
7.34–7.37 (m, 1H, ArH), 7.41–7.47 (m, 1H, ArH), 7.71 (s, 1H, 
ArH), 7.82–7.92 (m, 2H, ArH), 8.05 (d, J = 4.0Hz, 1H, ArH), 
8.22 (s, 1H, N=CH), 8.23–8.25 (m, 1H, ArH), 11.08 (s, 1H, 





Yield 85 %; m.p. 225–227 oC; IR (KBr, cm–1): 3246, 3158, 
2993, 2765, 1670, 1615, 1506, 1409, 1373, 1293, 1253, 
1167, 1140, 1090, 974, 851, 812, 739, 652; 1H NMR (400 
MHz, DMSO-d6) δ / ppm: 2.37 (s, 3H, CH3), 4.06 (s, 2H, CH2), 
5.49 (s, 2H, N-CH2), 6.87–6.90 (m, 1H, ArH), 7.06–7.13 (m, 
1H, ArH), 7.16–7.29 (m, 3H, ArH), 7.51–7.56 (m, 1H, ArH), 
7.81 (d, J = 7.6 Hz, 1H, ArH), 7.87–7.91 (m, 2H, ArH), 8.02 
(d, J = 4.0 Hz, 1H, ArH), 8.17–8.20 (m, 1H, ArH), 8.21 (s, 1H, 






Yield 81 %; m.p. 220–222 oC; IR (KBr, cm–1): 3155, 3068, 
2942, 1667, 1541, 1505, 1471, 1255, 1230, 1165, 1046, 905, 
851; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.37 (s, 3H, 
CH3), 3.66 (s, 3H, OCH3), 4.08 (s, 2H, CH2), 5.45 (s, 2H, N-
CH2), 6.84–6.89 (m, 2H, ArH), 7.04–7.06 (m, 1H, ArH), 7.21–
7.30 (m, 2H, ArH), 7.45 (d, J = 8.8 Hz, 1H, ArH), 7.73 (s, 1H, 
ArH), 7.79–7.85 (m, 2H, ArH), 8.04 (d, J = 4.0 Hz, 1H, ArH), 
8.20 (s, 1H, N=CH), 11.05 (s, 1H, NH), 11.32 (s, 1H, CONH); 





Yield 86 %; m.p. 195–197 oC; IR (KBr, cm–1): 3152, 3095, 
3064, 2939, 1669, 1586, 1507, 1485, 1472, 1318, 1293, 938, 
853; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.38 (s, 3H, 
CH3), 3.67 (s, 3H, OCH3), 4.12 (s, 2H, CH2), 5.49 (s, 2H, N-
CH2), 6.85–6.92 (m, 2H, ArH), 7.04–7.06 (m, 1H, ArH), 7.21–
7.30 (m, 2H, ArH), 7.45 (d, J = 8.8 Hz, 1H, ArH), 7.73 (s, 1H, 
ArH), 7.79–7.85 (m, 2H, ArH), 8.04 (d, J = 4.0 Hz, 1H, ArH), 
8.20 (s, 1H, N=CH), 11.05 (s, 1H, NH), 11.32 (s, 1H, CONH); 





Yield 87 %; m.p. 215–217 oC; IR (KBr, cm–1): 3154, 3059, 
2935, 1664, 1587, 1539, 1456, 1436, 1165, 1138, 1071, 765; 
1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.37 (s, 3H, CH3), 
3.56 (s, 3H, OCH3), 4.09 (s, 2H, CH2), 5.40 (s, 2H, N-CH2), 
6.82–6.89 (m, 2H, ArH), 7.16–7.20 (m, 2H, ArH), 7.40 (d, J = 
8.8 Hz, 1H, ArH), 7.50–7.53 (m, 2H, ArH), 7.79 (s, 1H, ArH), 
7.89–7.93 (m, 2H, ArH) 8.04 (d, J = 4.0 Hz, 1H, ArH), 8.22 (s, 
1H, N=CH) 11.05 (s, 1H, NH), 11.32 (s, 1H, CONH); ESI-MS: 
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Yield 82 %; m.p. 215–217 oC; IR (KBr, cm–1): 3153, 3062, 
2938, 1669, 1587, 1560, 1473, 1443, 1202, 1101, 936, 858, 
702; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.35 (s, 3H, 
CH3), 4.06 (s, 2H, CH2), 5.43 (s, 2H, N-CH2), 6.82–6.88 (m, 
2H, ArH), 7.04–7.06 (m, 1H, ArH), 7.20–7.32 (m, 2H, ArH), 
7.43 (d, J = 8.8 Hz, 1H, ArH), 7.70 (s, 1H, ArH), 7.74–7.80 (m, 
2H, ArH), 8.06 (d, J = 4.0 Hz, 1H, ArH), 8.22 (s, 1H, N=CH), 
11.07 (s, 1H, NH), 11.36 (s, 1H, CONH); ESI-MS: m / z 568.15 





Yield 88 %; m.p. 195–197 oC; IR (KBr, cm–1): 3156, 3065, 
2945, 1667, 1589, 1558, 1445, 1407, 1259, 1141, 973, 880, 
670; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 2.39 (s, 3H, 
CH3), 4.12 (s, 2H, CH2), 5.49 (s, 2H, N-CH2), 6.85–6.92 (m, 
2H, ArH), 7.04–7.06 (m, 1H, ArH), 7.21–7.30 (m, 2H, ArH), 
7.45 (d, J = 8.8Hz, 1H, ArH), 7.73 (s, 1H, ArH), 7.79–7.85 (m, 
2H, ArH), 8.04 (d, J = 4.0 Hz, 1H, ArH), 8.20 (s, 1H, N=CH), 
11.05 (s, 1H, NH), 11.32 (s, 1H, CONH); ESI-MS: m / z 536.19 





Yield 84 %; m.p. 216–218 oC; IR (KBr, cm–1): 3154, 3063, 
2936, 2842, 2228, 1667, 1609, 1541, 1461, 1389, 1258, 
1167, 1113, 880, 787, 660; 1H NMR (400 MHz, DMSO-d6) δ 
/ ppm: 2.40 (s, 3H, CH3), 4.06 (s, 2H, CH2), 5.58 (s, 2H, N-
CH2), 6.91–6.98 (m, 1H, ArH), 7.32–7.36 (m, 3H, ArH), 7.81–
7.86 (m, 4H, ArH), 8.03–8.06 (m, 2H, ArH), 8.21 (s, 1H, 
N=CH), 8.36–8.41 (m, 1H, ArH), 11.13 (s, 1H, NH), 11.34 (s, 
1H, CONH); ESI-MS: m / z 525.24 (M+) (79Br). 
Anticancer Activity 
PROCEDURE OF THE SRB-ASSAY 
Anticancer evaluation was performed as per the procedure 
reported in literature.[9] Tumor cells (human breast cancer 
cell line MCF-7) were grown in tissue culture flasks in 
growth medium (RPMI-1640 with 2 mM glutamine, pH 7.4, 
10 % fetal calf serum, 100 μg/mL streptomycin, and 100 
units / mL penicillin) at 37 oC under the atmosphere of 5 % 
CO2 and 95 % relative humidity employing a CO2 incubator. 
The cells at subconfluent stage were harvested from the 
flask by treatment with trypsin (0.05 % trypsin in PBS con-
taining 0.02 % EDTA) and placed in growth medium. The 
cells with more than 97 % viability (trypan blue exclusion) 
were used for cytotoxicity studies. An aliquot of 100 μL of 
cells were transferred to a well of 96-well tissue culture 
plate. The cells were allowed to grow for one day at 37 oC 
in a CO2 incubator as mentioned above. The test materials 
at different concentrations were then added to the wells 
and cells were further allowed to grow for another 48 h. 
Suitable blanks and positive controls were also included. 
Each test was performed in triplicate. The cell growth was 
stopped by gently layering of 50 μL of 50 % trichloroacetic 
acid. The plates were incubated at 4 oC for an hour to fix the 
cells attached to the bottom of the wells. Liquids of all the 
wells were gently pipette out and discarded. The plates 
were washed five times with doubly distilled water to re-
move TCA, growth medium, etc. and were air-dried. 100 μL 
of SRB solution (0.4 % in 1 % acetic acid) was added to each 
well and the plates were incubated at ambient tempera-
ture for half an hour. The unbound SRB was quickly re-
moved by washing the wells five times with 1 % acetic acid. 
Plates were air dried, tris-buffer (100 μL of 0.01 M, pH 10.4) 
was added to all the wells and plates were gently stirred for 
5 min on a mechanical stirrer. The optical density was 
measured on ELISA reader at 540 nm. The cell growth at 
absence of any test material was considered 100 % and in 
turn growth inhibition was calculated. Percent growth cal-
culated on a plate-by-plate basis for test wells relative to 
control wells. Percent growth expressed as the ratio of av-
erage absorbance of the test well to the average absorb-
ance of the control wells 100. Using the six absorbance 
measurements (time zero, control growth [C] and test 
growth in the presence of drug at the four concentration 
levels [Ti]), the percentage growth calculated at each of the 
extracts and standard drug concentration levels. Percent-
age growth inhibition calculated as [Ti/C] × 100 %. 
 
RESULTS AND DISCUSSION 
Chemistry 
Synthesis of the 2-methyl-7-azaindolyl hydrazide 5 has 
been accomplished by the chemical reactions outlined in 
Scheme 1. Mannich reaction of 2-methyl-7-azaindole with 
N,N-dimethyl amine hydrochloride and paraformaldehyde 
gave N,N-dimethyl-1-(2-methyl-1H-pyrrolo[2,3-b] pyridin-
3-yl)methanamine 1 which on treatment with methyl io-
dide in alcohol followed by substitution with sodium cya-
nide in DMF furnished 2-methyl-7-azaindole-3-acetonitrile 
2. The acid hydrolysis of 2 gave 2-(2-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)acetic acid 3 which on esterification with 
methanol and catalytic amount of concentrated H2SO4, 
gave corresponding ester 4. Methyl ester 4 on treatment 
with hydrazine hydrate in methanol offered 2-methyl-7-
azaindolyl hydrazide 5 in excellent yield (Scheme 1). 
 The 2-methyl-7-azaindolyl hydrazide 5 initially 
reacted with various substituted aromatic aldehydes  
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N-1-substituted indole-3-carboxyaldehydes 7a–j in ethanol 
at reflux for 3-5 h in the presence of catalytic amount of 
acetic acid resulted in the formation of hydrazones 8a–l and 
9a–j, respectively. The various N-1-substituted-indole- 
3-carboxyaldehydes 7a–j selected as starting material  
were prepared by the Vilsmeier-Hack formylation of  
5-substituted indoles followed by N-protection with various 
substituted alkyl halides in presence of sodium hydride in 
THF as reaction medium (Scheme 2). The structures of all 
the synthesized compounds 8a–l and 9a–j were established 
by 1H NMR, IR and mass spectroscopy techniques. 
Spectroscopy Study 
It is previously well documented that N-acylhydrazones 
may exist as geometrical isomers (E/Z) with respect to the 
imine bonds and as conformational (cis/trans) isomers 
around the amide N−C(O) bond.[12] In 1H NMR spectrum of 
compound 8a, we observed two signals for imine protons 
(N=CH), -CH2-C(O) and some of the benzylidene protons, 
which is believed to be due to its existence as conformational 
isomers (rotation around N-C(O)) or geometrical isomers  
(E / Z, N=CH). 13C NMR spectrum of compound 8a also 
showed two sets of signals for most of its carbon nuclei. In 
1H NMR spectra of compound 8a, we observed a mixture of 
cis/trans isomers in unequal proportions in solution phase 
at room temperature. Thus, we studied the possibility of 
isomerization in solution phase by analyzing sample at var-
ious temperatures while heating and cooling. The temper-
ature study revealed that with the rise in temperature up 
to 90 °C only one isomer exists predominantly but at 50 °C 
and 70 °C, mixture of isomers observed and similarly during 
cooling conversion of single isomer to mixture of isomers 
was observed (Figure 2). 
 
BIOLOGICAL EVALUATION 
In vitro Anticancer Activity 
The in vitro anti-proliferative activity of the synthesized 
compounds was evaluated against human breast cancer 
cell line MCF-7 and normal Vero monkey cell line by em-
ploying sulforhodamine B (SRB) protein assay method.[13] 
Adriamycin a potent anticancer drug was used as reference 
standard. The anticancer activity of tested compounds is 
given by three parameters, GI50 (molar concentration of the 
compound that inhibits 50 % net cell growth), TGI (molar 
concentration of the compound leading to total inhibition) 
and LC50 (molar concentration of the compound leading to 
 
Scheme 1. Synthesis of 2-methyl-7-azaindolyl hydrazide; 
Reagents and conditions: a) HN(CH3)2.HCl, HCHO, MeOH; 
b) EtOH, CH3I, NaCN, DMF; c) Aq. HCl, d) MeOH, H2SO4;  
e) NH2NH2.H2O. 
 
Scheme 2. Synthesis of 7-azaindolyl hydrazones; Reagents 
and conditions: a) DMF, POCl3; b) NaH, Dry THF 0 oC-RT;  
c) EtOH, glacial AcOH; d) EtOH, glacial AcOH, Reflux. 
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50 % net cell death) and the results are summarized in Table 
1. From the results obtained (Table 1), it is clear that all the 
hydrazones reduce the cancer cell viability significantly 
with GI50 values ranging from 22.3 - 81.0 μM. SRB assay 
reveals that most of the hydrazones of N-1-substituted 
indole-3-carboxyaldehydes 9f, 9g, 9h, 9c, and 9j are potent 
against MCF-7 cell line with GI50 values less than 40 μM. 
Remaining compounds have shown moderate to weak 
cytotoxicity against MCF-7 cell line ranging from 58.5– 
81 μM. 
 A comparison of the TGI concentrations of the com-
pounds with adriamycin was also done. Most of the com-
pounds were inactive and a few displayed weak activity 
against the MCF-7 cell line. Compounds 9f, 9g, 9h, 9c and 
9j exhibited weak activity (TGI = 56.6, 59.5, 65.5, 70.7, and 
94.6 µM respectively) against MCF-7 cell line. All the other 
compounds found inactive (TGI > 100 μM) as compared to 
standard drug adriamycin (TGI = 25.9 μM). 
 The LC50 concentrations of the compounds were also 
compared to that of adriamycin to get a sign of the cyto-
toxic effects of these compounds against the MCF-7 cell 
line. Most of the compounds were found to be inactive 
(LC50 > 100 µM) except compound 9f and 9g as like 
adriamycin (LC50 = 92.8 µM) against the MCF-7 cell line. 
 Most of the marketed drugs affect the normal cell 
growth, which serves to be a major disadvantage in the 
evolution of anticancer drug development. Therefore, we 
have ensured the selectivity of active compounds by in 
vitro screening against the normal Vero Monkey cell line 
(Table 1). These results demonstrate that the synthesized  
 
Table 1. Anticancer activity profile of synthesized hydrazone derivatives against MCF-7 breast cancer cell line. 
Entry 
Substitutions MCF-7 Vero (Normal) 
R R1 R2 GI50(a) LC50(b) TGI(c) GI50(a) LC50(b) TGI(c) 
8a – – 2,4-(Cl)2C6H3 75.0 > 100 > 100 NT NT NT 
8b – – 3,4-(F)2C6H3 73.5 > 100 > 100 NT NT NT 
8c – – 3,4,5-(MeO)3C6H2 72.5 > 100 > 100 NT NT NT 
8d – – 3,4-(O-CH2-O)C6H3 69.8 > 100 > 100 NT NT NT 
8e – – 2,4-(F)2C6H3 78.7 > 100 > 100 NT NT NT 
8f – – 3-NO2-C6H4 68.9 > 100 > 100 NT NT NT 
8g – – 2,4,6-(MeO)3C6H2 75.2 > 100 > 100 NT NT NT 
8h – – 3-Br-C6H4 70.4 > 100 > 100 NT NT NT 
8i – – 4-OH-C6H4 58.5 > 100 > 100 NT NT NT 
8j – – 3-F-4-OMe-C6H3 76.2 > 100 > 100 NT NT NT 
8k – – 3-OMe-4-OH-C6H3 62.6 > 100 > 100 NT NT NT 
8l – – 4-CN-C6H4 60.1 > 100 > 100 NT NT NT 
9a H 4-ClC6H4CH2 – 72.1 > 100 > 100 NT NT NT 
9b H 4-FC6H4CH2 – 80.2 > 100 > 100 NT NT NT 
9c H 2,4-(Cl)2C6H3CH2 – 30.2 > 100 70.7 59.4 > 100 > 100 
9d H 2,4-(F)2C6H3CH2 – 77.8 > 100 > 100 NT NT NT 
9e 5-OMe 2,4-(Cl)2C6H3CH2 – 73.2 > 100 > 100 NT NT NT 
9f 5-OMe 2,4-(F)2C6H3CH2 – 22.3 90.3 56.6 23.8 75.9 68.2 
9g 5-OMe 4-BrC6H4CH2 – 24.9 94.0 59.5 18.2 86.8 45.5 
9h 5-Br 2,4-(Cl)2C6H3CH2 – 29.6 > 100 65.5 25.1 99.4 52.3 
9i 5-Br 2,4-(F)2C6H3CH2 – 81.0 > 100 > 100 NT NT NT 
9j 5-Br 4-CNC6H4CH2 – 37.8 > 100 94.6 22.5 > 100 77.6 
ADR – – – < 0.1 92.8 25.9 19 52.5 > 10 
(a) Concentrations in µM; Growth inhibition of 50 % (GI50) calculated from [(Ti – Tz) / (C – Tz)] × 100 = 50. 
(b) Concentration of drug resulting in a 50 % reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) calculated 
from [(Ti – Tz) / Tz] × 100 = –50. 
(c) Drug concentration resulting in total growth inhibition (TGI) will calculated from Ti = Tz. 
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7-azaindolyl hydrazine derivatives 9f, 9g, 9h, 9c, and 9j 




In conclusion, a series of 7-azaindolyl hydrazones were 
prepared and their structures were analyzed by FT-IR, 1H 
NMR and mass spectral data. All the compounds were 
screened for their anticancer potential against MCF-7 
induced breast carcinoma. All the compounds screened 
were found to possess notable anticancer potential. 
Compounds 9f, 9g, 9h, 9c, and 9j were significantly active 
against MCF-7 cell line with GI50 values ranging from 22.3–
37.8 µM and TGI values 56.6–94.6 µM. Thus, these 
compounds constitute an interesting template and may be 
helpful for the design and development of new therapeutic 
tools against cancer. 
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